This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
Novavax Vaccine to Get U.S. Approval? ETFs to Benefit
by Sanghamitra Saha
Novavax (NVAX) is reportedly set to receive the fourth authorization for COVID-19 vaccine in the United States.
5 Niche ETFs Dominating the Current Market Rally
by Sweta Killa
We have highlighted five ETFs from different zones that were at the heart of the latest market rally over the past week and will likely to do so if the current trends prevail.
Top-Performing ETFs of Last Week
by Sanghamitra Saha
Last week was upbeat for Wall Street with the S&P 500 and the Dow Jones closing out at a record high.
Moderna ETFs to Gain on Positive 'Real-World' Study Data
by Sweta Jaiswal, FRM
Positive coronavirus vaccine progress by Moderna (MRNA) grabs investors' attention.
What's in Store for COVID-Themed ETFs as New Cases Rise?
by Sweta Jaiswal, FRM
The first half of 2021 is expected to continue bearing the brunt of the coronavirus outbreak considering the pandemic's renewed resurgence thanks to variants. Thus, a COVID-themed ETF could be a smart pick.
Novavax ETFs to Shine Bright on Positive Vaccine Update
by Sweta Jaiswal, FRM
Investors are closely tracking the progress in coronavirus vaccine development and distribution amid the pandemic.
6 ETF Areas That Are on High Momentum
by Sanghamitra Saha
The first month of 2021 was pretty volatile. While stocks were at their all-time highs in first part of January, some downbeat economic data points as well as the retail trading frenzy in some specific stocks in the month-end disbalanced the market momentum finally.
5 Sector ETFs That Outperformed in a Volatile January
by Sweta Killa
The three indices logged in their worst week since October, dropping more than 3% each, sending the Dow Jones and S&P 500 into the red for the first month of 2021.
Top-Performing ETFs of Last Week
by Sanghamitra Saha
Simple profit-booking and some warnings from the too-big-to-fail companies probably led to crash in Wall Street last week.
Novavax (NVAX) ETFs to Rise on Impressive Coronavirus Vaccine Update
by Sweta Jaiswal, FRM
Investors are closely tracking the progress in coronavirus vaccine development amid the pandemic's renewed resurgence with multiple mutants.
Can Moderna ETFs Gain on COVID Vaccine Update Against Variants?
by Sweta Jaiswal, FRM
Positive coronavirus vaccine update from Moderna (MRNA) has hogged investors' attention.
COVID-Themed ETFs in Focus Amid Soaring Cases
by Sweta Jaiswal, FRM
The first half of 2021 is expected to continue bearing the brunt of the coronavirus outbreak. Thus, a COVID-themed ETF could be a smart pick.
Top Sector ETFs of Record-Setting Last Week
by Sanghamitra Saha
The S&P 500, the Dow Jones and the Nasdaq Composite -- all three indexes touched all-time closing highs to end last week.
COVID-Themed ETFs in Focus as Cases Soar Post Thanksgiving
by Sweta Jaiswal, FRM
The rest of 2020 and the beginning of 2021 are expected to continue bearing the brunt of the coronavirus outbreak. Thus, a COVID-themed ETF could be a smart pick.
Moderna ETFs to Shine on Vaccine News as Outbreak Worsens
by Sweta Jaiswal, FRM
Positive coronavirus vaccine progress from Moderna (MRNA) has hogged investors' attention.
Coronavirus-Themed ETFs in Focus as the Pandemic Worsens
by Sweta Jaiswal, FRM
The remainder of 2020 is expected to continue bearing the brunt of the coronavirus outbreak and therefore, a COVID-19-themed ETF could be a smart pick.
Moderna Expects COVID-19 Vaccine Data in November: ETFs to Gain
by Sweta Jaiswal, FRM
Positive comment on coronavirus vaccine progress from Moderna's (MRNA) CEO during The Wall Street Journal's annual Tech Live conference has gained investors attention and raised vaccine optimism.
5 Coronavirus-Themed ETFs That Can Fight the Pandemic Scares
by Sweta Jaiswal, FRM
It feels like the rest of 2020 will continue to bear the brunt of the coronavirus outbreak and therefore, a COVID-19-themed ETF could be a smart pick.
6 Sector ETFs Surviving the Market Rout
by Sweta Killa
Amid the uncertainties, a few sectors have survived last week's turmoil. We have highlighted six of that could be compelling picks for the weeks ahead as long as volatility persists.
Will Novavax ETFs Gain on Coronavirus Vaccine Progress?
by Sweta Jaiswal, FRM
Investors are closely tracking the progress in the coronavirus vaccine development amid the coronavirus outbreak.
Direxion Debuts CCON ETF, Expands COVID-19-Themed Product Base
by Sweta Jaiswal, FRM
In the current scenario of the rising work-from-home and online shopping trends, online learning, home entertainment, telemedicine and digital health services are slowly becoming the "new normal."
Moderna ETFs to Gain on New Positive COVID-19 Vaccine Data
by Sweta Jaiswal, FRM
Per the latest data from an early stage clinical trial, Moderna's experimental coronavirus vaccine is successfully producing neutralizing antibodies and T-cells in older adults.
Direxion Debuts CCOC ETF, Expands COVID-19-Themed Product Base
by Sweta Jaiswal, FRM
In the current scenario of the rising work-from-home and online shopping trends, online learning, home entertainment, telemedicine and digital health services are slowly becoming the "new normal."
Moderna ETFs to Shine on U.S. Contracts for Coronavirus Vaccine
by Sweta Jaiswal, FRM
Moderna has inked a $1.5-billion coronavirus vaccine supply agreement with the U.S. government.
Should You Invest in COVID Themed ETFs?
by Neena Mishra
We highlight three new ETFs that seek to capitalize on coronavirus